Clinical Pharmacokinetics

, Volume 51, Issue 3, pp 163–174

Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy

  • André B. P. van Kuilenburg
  • Peter Häusler
  • Andreas Schalhorn
  • Michael W. T. Tanck
  • Johannes H. Proost
  • Christoph Terborg
  • Detlev Behnke
  • Wolfgang Schwabe
  • Kati Jabschinsky
  • Jan Gerard Maring
Original Research Article

DOI: 10.1007/BF03257473

Cite this article as:
van Kuilenburg, A.B.P., Häusler, P., Schalhorn, A. et al. Clin Pharmacokinet (2012) 51: 163. doi:10.1007/BF03257473
  • 200 Downloads

Abstract

Background and Objective

Dihydropyrimidine dehydrogenase (DPD) is the initial enzyme in the catabolism of 5-fluorouracil (5FU) and DPD deficiency is an important pharmacogenetic syndrome. So far, only very limited information is available regarding the pharmacokinetics of 5FU in patients with a (partial) DPD deficiency and no limited sampling models have been developed taking into account the non-linear pharmacokinetic behaviour of 5FU. The aim of this study was to evaluate the pharmacokinetics of 5FU and to develop a limited sampling strategy to detect decreased 5FU elimination in patients with a c.1905+1G>A-related DPD deficiency.

Methods

Thirty patients, heterozygous for the C.1905+1G>A mutation in DPYD, and 18 control patients received a dose of 5FU 300 mg/m2 and/or 5FU 450 mg/m2, followed by pharmacokinetic analysis of the 5FU plasma levels. A population pharmacokinetic analysis was performed in order to develop a compartmental pharmacokinetic model suitable for a limited sampling strategy. Clinical aspects of treating DPD-deficient patients with 5FU-based chemotherapy were assessed from the retrospectively collected clinical data.

Results

In a two-compartment model with Michaelis-Menten elimination, the mean maximum enzymatic conversion capacity (Vmax) value was 40% lower in DPD-deficient patients compared with controls (p < 0.001). Using a limited sampling strategy, with Vmax values calculated from 5FU concentrations at 30 or 60 minutes, significant differences were observed between DPD-deficient patients and controls at both dose levels (p < 0.001). The positive predictive value and negative predictive value for Vmax, calculated from 5FU levels at 60 minutes, were 96% and 88%, respectively, in patients treated with a single dose of 5FU 300 mg/m2. All seven DPD-deficient patients (two males and five females) who had been genotyped prior to initiation of standard 5FU-containing chemotherapy developed grade 3–4 toxicity, with one case of lethal toxicity in a female patient. No grade 4 toxicity or lethal outcome was observed in 13 DPD-deficient patients treated with reduced doses of 5FU. The average dose of 5FU in DPD-deficient patients with mild toxicity (grade ≤2) was 61 ± 16% of the normal 5FU dose (n= 10).

Conclusions

Profound differences in the elimination of 5FU could be detected between DPD-deficient patients and control patients. Pharmacokinetic 5FU profiling, using a single 5FU concentration at 60 minutes, may be useful for identification of DPD-deficient patients in order to reduce severe toxicity. Furthermore, treatment of DPD-deficient patients with standard 5FU-containing chemotherapy was associated with severe (lethal) toxicity.

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • André B. P. van Kuilenburg
    • 1
  • Peter Häusler
    • 2
  • Andreas Schalhorn
    • 3
  • Michael W. T. Tanck
    • 4
  • Johannes H. Proost
    • 5
  • Christoph Terborg
    • 6
  • Detlev Behnke
    • 7
  • Wolfgang Schwabe
    • 7
  • Kati Jabschinsky
    • 7
  • Jan Gerard Maring
    • 8
  1. 1.Academic Medical Center, Emma Children’s Hospital and Department of Clinical ChemistryUniversity of AmsterdamAmsterdamThe Netherlands
  2. 2.Clondiag GmbHJenaGermany
  3. 3.Med. Klinik IIIUniversity Hospital GroßhadernMunichGermany
  4. 4.Academic Medical Center, Department of Clinical Epidemiology, Biostatistics and BioinformaticsUniversity of AmsterdamAmsterdamThe Netherlands
  5. 5.Department of Pharmacokinetics, Toxicology and TargetingUniversity of GroningenGroningenThe Netherlands
  6. 6.Klinik für NeurologieAsklepios Klinik St. GeorgHamburgGermany
  7. 7.Department of Research and DevelopmentOncoscreen GmbHJenaGermany
  8. 8.Department of PharmacyDiaconessen Hospital Meppel and Bethesda Hospital HoogeveenMeppelThe Netherlands
  9. 9.Laboratory Genetic Metabolic DiseasesAcademic Medical CenterAmsterdamThe Netherlands

Personalised recommendations